Valuation: Alaunos Therapeutics, Inc.

Market Cap 4.67M 4.04M 3.79M 3.45M 6.49M 447M 6.59M 44.46M 17.38M 224M 17.55M 17.17M 744M P/E 2024
-0.65x
P/E 2025 -1.47x
Enterprise Value 3.29M 2.84M 2.67M 2.43M 4.57M 315M 4.64M 31.28M 12.23M 158M 12.35M 12.08M 523M EV / Sales 2024
195,938,500x
EV / Sales 2025 1,164,761,400x
Free-Float
84.09%
Yield 2024 *
-
Yield 2025 -
1 day-2.01%
1 week-2.01%
Current month+3.72%
1 month-8.45%
3 months-21.05%
6 months-24.12%
Current year-39.63%
1 week 1.91
Extreme 1.9086
2.02
1 month 1.81
Extreme 1.81
2.19
Current year 1.81
Extreme 1.81
4.04
1 year 1.67
Extreme 1.67
4.59
3 years 1.31
Extreme 1.3137
32.85
5 years 1.31
Extreme 1.3137
601.5
10 years 1.31
Extreme 1.3137
1,182
Manager TitleAgeSince
Chief Executive Officer 63 01/07/2025
Director of Finance/CFO 41 21/02/2025
Director TitleAgeSince
Director/Board Member 57 15/12/2020
Chairman 63 21/09/2023
Director/Board Member 72 04/02/2021
Date Insider Type Main position Quantity % Market Cap.
06/08/26 Free

Chief Executive Officer

4,363 0.1787%
23/07/26 Free

Director

8,138 0.3332%
23/07/26 Free

Chief Executive Officer

4,568 0.1870%
Change 5-day change 1-year change 3-year change Capi.($)
-2.01%-2.01%-13.33%-90.65% 4.67M
-1.90%+2.85%+62.82%+104.13% 70.07B
-3.21%-4.32%+31.85%+57.27% 52.87B
-2.05%-5.61%-3.18%+449.71% 27.02B
-1.27%-1.57%+45.90%+8.25% 23.61B
+1.05%-0.62%-18.00%-11.93% 23.38B
+3.81%+20.97%+266.37%+531.28% 19.43B
+0.10%+1.40%+35.36%-19.94% 18.75B
-0.95%-3.52%+19.93%+594.00% 15.85B
+1.24%-5.23%+33.75%+137.66% 12.7B
Average -0.52%+1.75%+46.15%+175.98% 26.37B
Weighted average by Cap. -1.09%+0.55%+50.23%+164.99%

Financials

2024 2025
Net sales 0.01 0.01 0.01 0.01 0.01 0.96 0.01 0.1 0.04 0.48 0.04 0.04 1.59 0 0 0 0 0.01 0.48 0.01 0.05 0.02 0.24 0.02 0.02 0.8
Net income -4.68M -4.04M -3.8M -3.45M -6.49M -447M -6.6M -44.5M -17.4M -224M -17.57M -17.19M -745M -4.18M -3.61M -3.39M -3.08M -5.8M -399M -5.89M -39.71M -15.53M -200M -15.68M -15.34M -665M
Net Debt -1.09M -942K -885K -805K -1.51M -104M -1.54M -10.38M -4.06M -52.24M -4.1M -4.01M -174M -1.38M -1.2M -1.12M -1.02M -1.92M -132M -1.95M -13.17M -5.15M -66.32M -5.2M -5.09M -220M
Logo Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.
Employees
1
Date Price Change Volume
14/08/26 US$1.930 -3.02% 11,715
13/08/26 US$1.990 -0.50% 7,774
12/08/26 US$2.000 +1.52% 7,203
11/08/26 US$1.970 -0.51% 5,224
10/08/26 US$1.980 -0.50% 10,237

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRT Stock